Cargando…

A Path to Implement Precision Child Health Cardiovascular Medicine

Congenital heart defects (CHDs) affect approximately 1% of live births and are a major source of childhood morbidity and mortality even in countries with advanced healthcare systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs is multifactorial, involving genetic, epigenetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Touma, Marlin, Reemtsen, Brian, Halnon, Nancy, Alejos, Juan, Finn, J. Paul, Nelson, Stanley F., Wang, Yibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451507/
https://www.ncbi.nlm.nih.gov/pubmed/28620608
http://dx.doi.org/10.3389/fcvm.2017.00036
_version_ 1783240198769868800
author Touma, Marlin
Reemtsen, Brian
Halnon, Nancy
Alejos, Juan
Finn, J. Paul
Nelson, Stanley F.
Wang, Yibin
author_facet Touma, Marlin
Reemtsen, Brian
Halnon, Nancy
Alejos, Juan
Finn, J. Paul
Nelson, Stanley F.
Wang, Yibin
author_sort Touma, Marlin
collection PubMed
description Congenital heart defects (CHDs) affect approximately 1% of live births and are a major source of childhood morbidity and mortality even in countries with advanced healthcare systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs is multifactorial, involving genetic, epigenetic, and/or environmental contributors. Clear dissection of the underlying mechanism is a powerful step to establish individualized therapies. However, the majority of CHDs are yet to be clearly diagnosed for the underlying genetic and environmental factors, and even less with effective therapies. Although the survival rate for CHDs is steadily improving, there is still a significant unmet need for refining diagnostic precision and establishing targeted therapies to optimize life quality and to minimize future complications. In particular, proper identification of disease associated genetic variants in humans has been challenging, and this greatly impedes our ability to delineate gene–environment interactions that contribute to the pathogenesis of CHDs. Implementing a systematic multileveled approach can establish a continuum from phenotypic characterization in the clinic to molecular dissection using combined next-generation sequencing platforms and validation studies in suitable models at the bench. Key elements necessary to advance the field are: first, proper delineation of the phenotypic spectrum of CHDs; second, defining the molecular genotype/phenotype by combining whole-exome sequencing and transcriptome analysis; third, integration of phenotypic, genotypic, and molecular datasets to identify molecular network contributing to CHDs; fourth, generation of relevant disease models and multileveled experimental investigations. In order to achieve all these goals, access to high-quality biological specimens from well-defined patient cohorts is a crucial step. Therefore, establishing a CHD BioCore is an essential infrastructure and a critical step on the path toward precision child health cardiovascular medicine.
format Online
Article
Text
id pubmed-5451507
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54515072017-06-15 A Path to Implement Precision Child Health Cardiovascular Medicine Touma, Marlin Reemtsen, Brian Halnon, Nancy Alejos, Juan Finn, J. Paul Nelson, Stanley F. Wang, Yibin Front Cardiovasc Med Cardiovascular Medicine Congenital heart defects (CHDs) affect approximately 1% of live births and are a major source of childhood morbidity and mortality even in countries with advanced healthcare systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs is multifactorial, involving genetic, epigenetic, and/or environmental contributors. Clear dissection of the underlying mechanism is a powerful step to establish individualized therapies. However, the majority of CHDs are yet to be clearly diagnosed for the underlying genetic and environmental factors, and even less with effective therapies. Although the survival rate for CHDs is steadily improving, there is still a significant unmet need for refining diagnostic precision and establishing targeted therapies to optimize life quality and to minimize future complications. In particular, proper identification of disease associated genetic variants in humans has been challenging, and this greatly impedes our ability to delineate gene–environment interactions that contribute to the pathogenesis of CHDs. Implementing a systematic multileveled approach can establish a continuum from phenotypic characterization in the clinic to molecular dissection using combined next-generation sequencing platforms and validation studies in suitable models at the bench. Key elements necessary to advance the field are: first, proper delineation of the phenotypic spectrum of CHDs; second, defining the molecular genotype/phenotype by combining whole-exome sequencing and transcriptome analysis; third, integration of phenotypic, genotypic, and molecular datasets to identify molecular network contributing to CHDs; fourth, generation of relevant disease models and multileveled experimental investigations. In order to achieve all these goals, access to high-quality biological specimens from well-defined patient cohorts is a crucial step. Therefore, establishing a CHD BioCore is an essential infrastructure and a critical step on the path toward precision child health cardiovascular medicine. Frontiers Media S.A. 2017-06-01 /pmc/articles/PMC5451507/ /pubmed/28620608 http://dx.doi.org/10.3389/fcvm.2017.00036 Text en Copyright © 2017 Touma, Reemtsen, Halnon, Alejos, Finn, Nelson and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Touma, Marlin
Reemtsen, Brian
Halnon, Nancy
Alejos, Juan
Finn, J. Paul
Nelson, Stanley F.
Wang, Yibin
A Path to Implement Precision Child Health Cardiovascular Medicine
title A Path to Implement Precision Child Health Cardiovascular Medicine
title_full A Path to Implement Precision Child Health Cardiovascular Medicine
title_fullStr A Path to Implement Precision Child Health Cardiovascular Medicine
title_full_unstemmed A Path to Implement Precision Child Health Cardiovascular Medicine
title_short A Path to Implement Precision Child Health Cardiovascular Medicine
title_sort path to implement precision child health cardiovascular medicine
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451507/
https://www.ncbi.nlm.nih.gov/pubmed/28620608
http://dx.doi.org/10.3389/fcvm.2017.00036
work_keys_str_mv AT toumamarlin apathtoimplementprecisionchildhealthcardiovascularmedicine
AT reemtsenbrian apathtoimplementprecisionchildhealthcardiovascularmedicine
AT halnonnancy apathtoimplementprecisionchildhealthcardiovascularmedicine
AT alejosjuan apathtoimplementprecisionchildhealthcardiovascularmedicine
AT finnjpaul apathtoimplementprecisionchildhealthcardiovascularmedicine
AT nelsonstanleyf apathtoimplementprecisionchildhealthcardiovascularmedicine
AT wangyibin apathtoimplementprecisionchildhealthcardiovascularmedicine
AT toumamarlin pathtoimplementprecisionchildhealthcardiovascularmedicine
AT reemtsenbrian pathtoimplementprecisionchildhealthcardiovascularmedicine
AT halnonnancy pathtoimplementprecisionchildhealthcardiovascularmedicine
AT alejosjuan pathtoimplementprecisionchildhealthcardiovascularmedicine
AT finnjpaul pathtoimplementprecisionchildhealthcardiovascularmedicine
AT nelsonstanleyf pathtoimplementprecisionchildhealthcardiovascularmedicine
AT wangyibin pathtoimplementprecisionchildhealthcardiovascularmedicine